29 papers in the library · 1 citation · publishing 2019-2026
Alcoholism & Drug Abuse Weekly October 7, 2019 Alison Knopf
Like its predecessor intravenous ketamine, an anesthetic that has been used off‐label to treat depression, esketamine has shown great promise in treating a disease that can destroy quality of life and lead to suicide. The Food and Drug Administration (FDA) approved esketamine (Spravato) last spring for treating depression that is resistant to traditional treatments.
Alcoholism & Drug Abuse Weekly April 8, 2019 Alison Knopf
Daily use of marijuana (cannabis) is associated with a greater than three times increased risk of psychotic disorder compared to never users, according to a study published in Lancet Psychiatry. This risk increased to nearly five times if high‐potency cannabis was used. Across the 11 sites included in the study, if high‐potency cannabis were not available, 12.2 percent of cases of first‐episode...
The Brown University Child and Adolescent Behavior Letter April 1, 2019 Alison Knopf
Lasting effects of adolescent cannabis use are even more pronounced than those for alcohol, researchers suggest in a new study of the role of impaired cognition on substance use.
Alcoholism & Drug Abuse Weekly March 4, 2019 Alison Knopf
Lasting effects of adolescent cannabis use are even more pronounced than those for alcohol, researchers suggest in a new study of the role of impaired cognition on substance use. According to the study, published in the February issue of the American Journal of Psychiatry, both alcohol and cannabis misuse are related to impaired cognition, but is this cause or correlation? To infer cause,...